Tegavivint

Generic Name: Tegavivint

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₆N_₄O_₆S_₂

CAS Number: 1227637-23-1

Unique Ingredient Identifier: 18AP231HUP

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: Tegavivint
Drug: Pembrolizumab

First Posted Date: 2023-04-04

Last Posted Date: 2024-08-27

Lead Sponsor: Iterion Therapeutics

Target Recruit Count: 108

Registration Number: NCT05797805

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

and more 5 locations

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Phase 1

Recruiting

Conditions: Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Drug: Tegavivint

First Posted Date: 2023-03-06

Last Posted Date: 2023-12-29

Lead Sponsor: Lapo Alinari

Target Recruit Count: 20

Registration Number: NCT05755087

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Phase 1

Active, not recruiting

Conditions: Recurrent Leukemia
Refractory Leukemia

Interventions: Drug: Decitabine
Drug: Tegavivint

First Posted Date: 2021-05-05

Last Posted Date: 2024-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT04874480

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Phase 1

Recruiting

Conditions: Neuroblastoma
Refractory Desmoid Fibromatosis
Wilms Tumor
Colorectal Carcinoma
Recurrent Hepatoblastoma
Recurrent Malignant Solid Neoplasm
Recurrent Osteosarcoma
Refractory Hepatocellular Carcinoma
Refractory Osteosarcoma
Solid Pseudopapillary Neoplasm of the Pancreas

Interventions: Procedure: Biospecimen Collection
Procedure: Dual X-ray Absorptiometry
Drug: Tegavivint
Procedure: X-Ray Imaging

First Posted Date: 2021-04-20

Last Posted Date: 2024-10-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 147

Registration Number: NCT04851119

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 18 locations

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Drug: Osimertinib
Drug: Tegavivint

First Posted Date: 2021-03-03

Last Posted Date: 2023-12-11

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT04780568

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059

Phase 1

Completed

Conditions: Desmoid Tumor

Interventions: Drug: Tegavivint

First Posted Date: 2018-03-09

Last Posted Date: 2023-03-01

Lead Sponsor: Iterion Therapeutics

Target Recruit Count: 24

Registration Number: NCT03459469

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy